Abstract Details

Title Cognitive and Neuropsychiatric Changes Related to COVID-19 in Patients Evaluated at a Referral Center in São Paulo, Brazil.

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P2 - Poster Session 2 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-012

Objective To evaluate cognitive and neuropsychiatric changes in patients with neurological disease after covid-19.

Background Cognitive dysfunction and brain fog, caracterized by fatigue, impaired memory and lack of concentration, are the most common symptoms of long covid.

Design/Methods A longitudinal prospective study designed to compare the cognitive performance after covid-19, based on cognitive complaints. Patients aged 18 to 65 years old (y.o.) without a history of neurological or psychiatric disorder were included, illiterate individuals were excluded. The Beck Anxiety and Depression Inventories (BAI and BDI), the Addenbrooke´s Cognitive Examination-Revised (ACE-R), the Trail Making Test (TMT) and the Mini-Mental State Examination (MMSE) were applied at 0, 3, and 6 months.

Results Fifty-eight patients were included, 63.97% women, 72.41% with cognitive complaints. The mean age was 46 y.o. (SD 9.82), median of 45.50 y.o, the mean educational level was 14.17 years (SD 3.87), median of 15 years, and the mean time between the first covid-19 symptom and the onset of neurological symptoms was 48.10 days (SD 61.37), median of 25.50 days. Patients without cognitive complaints scored lower on the BDI, with a mean of 7.36 (SD 7.19) and a median of 7, compared to patients with cognitive complaints, who had a mean of 13.69 (SD 9.20) and a median of 12.50 in the third assessment (6 months) (p = 0.045). Additionally, a trend was noted regarding cognitive complaints, anxiety, and depression in the second assessment (3 months), as well as a trend related to anxiety in the third assessment. In relation to cognitive complaints, there was a trend in MMSE performance at the third assessment, but no significant differences were found at other time points for this test or for the ACE-R or TMT.

Conclusions

Cognitive complaints after covid-19 infection were not a predictor of cognitive decline, but were related to neuropsychiatric changes.

Authors/Disclosures
FLAVIA E. DAHY, MD PRESENTER	Miss DAHY has nothing to disclose.
Aline d. Matos, MD	The institution of Dr. Matos has received research support from Hoffmann LaRoche.
Thais M. Romano, mestre e doutoranda	The institution of an immediate family member of Dr. Romano has received research support from CONSELHO NACIONAL DE PESQUISA E DESENVOLVIMENTO.
Rosa Marcusso N. Marcusso, Sr., MD	Prof. Marcusso has nothing to disclose.
Tatiane Assone, PhD	Dr. Assone has nothing to disclose.
Jorge Casseb, MD	Dr. Casseb has nothing to disclose.
Camila M. Romano, PhD	The institution of Dr. Romano has received research support from Conselho Nacional de Pesquisa e Desenvolvimento.
Augusto C. Penalva, PhD	Dr. Penalva has nothing to disclose.
Jerusa Smid, PhD (Private Office)	Dr. Smid has nothing to disclose.

��ɫ��

��ɫ��